Abstract | PURPOSE: METHODS: Eight patients (6 male, 2 female; mean age 45.7+/-17.5 years) were included in the study. Doxycycline (100 mg) was administered orally, twice a day, for 2 weeks and once a day for an additional 2 weeks. Clinical signs and symptoms were evaluated and scored (0-3) at baseline and after 4 weeks. Total sign (TSS) and total symptom (TSyS) scores were calculated. Tear samples and conjunctival impression cytologies were collected at baseline and after 4 weeks of treatment to evaluate MMP-9 and TIMP-1 expression and activity. RESULTS: An improvement in TSS (4.5+/-1.1 vs 2.7+/-1.5) and TSyS (6.6+/-1.3 vs. 3.1+/-1.9) was observed after 4 weeks, with significant amelioration of hyperemia, marginal blepharitis, and superficial punctuate keratopathy. Zymography revealed a decrease of MMP-9 activity after 4 weeks. MMP-9 mRNA and protein levels did not change, while an upregulation of TIMP-1 expression was observed. CONCLUSIONS: This study suggests that 4-week treatment with doxycycline significantly improved symptoms and signs in patients with chronic blepharitis in association with a decrease in MMP-9 activity. Upregulation of TIMP-1 is proposed as a possible mechanism of MMP-9 inactivation.
|
Authors | Alfonso Iovieno, Alessandro Lambiase, Alessandra Micera, Barbara Stampachiacchiere, Roberto Sgrulletta, Stefano Bonini |
Journal | European journal of ophthalmology
(Eur J Ophthalmol)
2009 Sep-Oct
Vol. 19
Issue 5
Pg. 708-16
ISSN: 1120-6721 [Print] United States |
PMID | 19787586
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Bacterial Agents
- Tissue Inhibitor of Metalloproteinase-1
- Matrix Metalloproteinase 9
- Doxycycline
|
Topics |
- Administration, Oral
- Adult
- Aged
- Anti-Bacterial Agents
(administration & dosage, therapeutic use)
- Blepharitis
(drug therapy, enzymology)
- Chronic Disease
- Doxycycline
(administration & dosage, therapeutic use)
- Female
- Humans
- Male
- Matrix Metalloproteinase 9
(metabolism)
- Middle Aged
- Tears
(enzymology)
- Tissue Inhibitor of Metalloproteinase-1
(metabolism)
- Treatment Outcome
- Up-Regulation
|